Publications

Detailed Information

Foxp3 Expression in p53-dependent DNA Damage Responses

DC Field Value Language
dc.contributor.authorJung, Da-Jung-
dc.contributor.authorJin, Dong-Hoon-
dc.contributor.authorHong, Seung-Woo-
dc.contributor.authorKim, Jee-Eun-
dc.contributor.authorKim, DaeJin-
dc.contributor.authorHwang, Young-Il-
dc.contributor.authorLee, Wang-Jae-
dc.contributor.authorKang, Jae-Seung-
dc.contributor.authorCho, Byung-Joo-
dc.contributor.authorShin, Jae-Sik-
dc.date.accessioned2012-07-10T01:44:03Z-
dc.date.available2012-07-10T01:44:03Z-
dc.date.issued2010-03-12-
dc.identifier.citationJOURNAL OF BIOLOGICAL CHEMISTRY; Vol.285, No.11; 7995-8002ko_KR
dc.identifier.issn0021-9258-
dc.identifier.urihttps://hdl.handle.net/10371/78684-
dc.description.abstractThe forkhead transcription factor, Foxp3, is thought to act as a master regulator that controls (suppresses) expression of the breast cancer oncogenes, SKP2 and HER-2/ErbB2. However, the mechanisms that regulate Foxp3 expression and thereby modulate tumor development remain largely unexplored. Here, we demonstrate that Foxp3 up-regulation requires p53 function, showing that Foxp3 expression is directly regulated by p53 upon DNA damage responses in human breast and colon carcinoma cells. Treatment with the genotoxic agents, doxorubicin or etoposide, induced Foxp3 expression in p53-positive carcinoma cells, but not in cells lacking p53 function. Furthermore, knock down of endogenous wild-type p53 using RNA interference abrogated Foxp3 induction by genotoxic agents, and exogenous expression of p53 in cells lacking p53 restored the responsiveness of Foxp3 to DNA-damaging stresses. In addition, Foxp3 knock down blunted the p53-mediated growth inhibitory response to DNA-damaging agents. These results suggest that induction of Foxp3 in the context of tumor suppression is regulated in a p53-dependent manner and implicate Foxp3 as a key determinant of cell fate in p53-dependent DNA damage responses.ko_KR
dc.description.sponsorshipThis work was supported by the Korean Science and Engineering Foundation
through the Tumor Immunity Medical Research Center at Seoul
National University College of Medicine Grant R13-2002-025-02001-0 and
Science Research Center Program through the Research Center for Womens
Diseases Grant R11-2005-017-03001.
ko_KR
dc.language.isoenko_KR
dc.publisherAMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INCko_KR
dc.titleFoxp3 Expression in p53-dependent DNA Damage Responsesko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor정다정-
dc.contributor.AlternativeAuthor진동훈-
dc.contributor.AlternativeAuthor홍승우-
dc.contributor.AlternativeAuthor김지은-
dc.contributor.AlternativeAuthor신재식-
dc.contributor.AlternativeAuthor김대진-
dc.contributor.AlternativeAuthor조병주-
dc.contributor.AlternativeAuthor황영일-
dc.contributor.AlternativeAuthor강재승-
dc.contributor.AlternativeAuthor이왕재-
dc.identifier.doi10.1074/jbc.M109.047985-
dc.citation.journaltitleJOURNAL OF BIOLOGICAL CHEMISTRY-
dc.description.citedreferenceOu-Yang HF, 2009, MOL CELL BIOCHEM, V320, P109, DOI 10.1007/s11010-008-9912-4-
dc.description.citedreferenceIto T, 2008, IMMUNITY, V28, P870, DOI 10.1016/j.immuni.2008.03.018-
dc.description.citedreferenceKaranikas V, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-19-
dc.description.citedreferenceZuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538-
dc.description.citedreferenceLiu Y, 2007, PHARMACOGENOMICS, V8, P1485, DOI 10.2217/14622416.8.11.1485-
dc.description.citedreferenceHinz S, 2007, CANCER RES, V67, P8344-
dc.description.citedreferenceKinyamu HK, 2007, MOL CELL BIOL, V27, P4891, DOI 10.1128/MCB.02162-06-
dc.description.citedreferenceZuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034-
dc.description.citedreferenceListon A, 2007, CURR OPIN IMMUNOL, V19, P176, DOI 10.1016/j.coi.2007.02.005-
dc.description.citedreferenceProvinciali M, 2007, CANCER RES, V67, P2022, DOI 10.1158/0008-5472.CAN-06-2601-
dc.description.citedreferenceTraub F, 2006, BREAST CANCER RES TR, V99, P185, DOI 10.1007/s10549-006-9202-3-
dc.description.citedreferenceKojima K, 2006, BLOOD, V108, P993, DOI 10.1182/blood-2005-12-5148-
dc.description.citedreferenceWu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042-
dc.description.citedreferenceMantel PY, 2006, J IMMUNOL, V176, P3593-
dc.description.citedreferenceHarris SL, 2005, ONCOGENE, V24, P2899-
dc.description.citedreferenceFontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016-
dc.description.citedreferenceChoi BM, 2005, BIOCHEM BIOPH RES CO, V327, P1066, DOI 10.1016/j.bbrc.2004.12.106-
dc.description.citedreferenceGondek DC, 2005, J IMMUNOL, V174, P1783-
dc.description.citedreferenceNagaoka H, 2005, P NATL ACAD SCI USA, V102, P2022-
dc.description.citedreferenceTaams LS, 2005, CURR TOP MICROBIOL, V293, P115-
dc.description.citedreferenceThompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200-
dc.description.citedreferenceJung MS, 2004, J BIOL CHEM, V279, P17765, DOI 10.1074/jbc.M305015200-
dc.description.citedreferenceFontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904-
dc.description.citedreferenceGrohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846-
dc.description.citedreferenceManzotti CN, 2002, EUR J IMMUNOL, V32, P2888-
dc.description.citedreferenceVousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864-
dc.description.citedreferencePark WS, 2000, GASTROENTEROLOGY, V119, P691-
dc.description.citedreferenceThornton AM, 1998, J EXP MED, V188, P287-
dc.description.citedreferenceHermeking H, 1997, MOL CELL, V1, P3-
dc.description.citedreferenceMCILWRATH AJ, 1994, CANCER RES, V54, P3718-
dc.description.citedreferenceELDEIRY WS, 1993, CELL, V75, P817-
dc.description.citedreferenceLOWE SW, 1993, CELL, V74, P957-
dc.description.citedreferenceHOLLSTEIN M, 1991, SCIENCE, V253, P49-
dc.description.tc8-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share